The Xarelto lawsuit status is in the midst of an interesting phase. In the federal court system, the first trial is scheduled to start on February 6, 2017. This is a significant milestone for the lawsuits, as it could result in the reversal of the drug’s approval. If the first trial is successful, then there will be a second. If not, the case will continue to stall.
The case is still in its early stages, but it may be part of multidistrict litigation.
That means that a jury might still have to decide whether the drug is safe or not. That means plaintiffs should file their lawsuits as soon as possible. Until the MDL has a final ruling, their claims can move forward. However, some plaintiffs will likely seek a trial in smaller groups of cases.
The settlement involving the Xarelto lawsuits has been delayed, but the judge has indicated that the cases will be prepared for early trials. This is because the attorneys will need to gather enough evidence to convince the jury. During the trial, the focus will be on the coordination of discovery by the drugmaker. This includes the review of millions of documents and marketing material. This means that the settlement is in the beginning stages.
A recent case involving the use of Xarelto is a good example of how this case will be resolved.
A woman in her fifties took the drug for more than a year before she suffered a fatal hemorrhagic stroke. Her husband filed a wrongful death lawsuit against Janssen Pharmaceuticals. The jury ruled that the drug was dangerous and that Janssen failed to warn her doctors about it.
A representative case will be prepared for early trial dates. This will give the attorneys a sense of how the jury will react to the evidence and testimony presented. Another key element in the Xarelto litigation is the coordination of discovery by the drugmaker. This will include the review of millions of internal documents and marketing materials. If you have a strong case, there is a good chance that you can win a sizable sum of money.
The manufacturers of Xarelto are liable for the complications it causes.
It was found that the medication caused irreversible bleeding. The company has paid out $775 million in damages and pleaded guilty. A settlement with these companies could lead to significant compensation for Xarelto patients. The drug makers have been convicted of negligence. Many people have been seriously injured by this medication. It’s been associated with a higher risk of heart problems.
A federal bellwether trial in January 2017 was a decision to throw out the Xarelto lawsuit. In this case, a plaintiff had developed deep vein thrombosis following hip surgery. She blamed the blood thinner for gastrointestinal bleeding and claimed that Xarelto had caused her acute blood loss. As a result, the drug was responsible for the onset of her gastrointestinal bleeding and her death.
In January 2018, a Pennsylvania state court judge ruled against Xarelto plaintiffs. She did this even though a majority of the cases are being heard in Louisiana. The class-action lawsuits were sent to Louisiana for discovery, which allowed the defendants to learn about the plaintiffs’ claims. The court ruled that Xarelto should pay damages for causing the damage. It’s also a win for Bayer in the Xarelto wrongful death case.
In the Federal Court, Eldon Fallon, a former United States attorney general, has been assigned to oversee the Xarelto lawsuits.
He has experience handling mass torts in Massachusetts and has defended the safety of the drug. While there have been many Xarelto lawsuits, a global settlement will end the Xarelto claims in the coming years. A $775 million settlement will settle 25,000 Xarelto cases and will not result in any further new litigation, and a settlement will settle all claims.
The Xarelto lawsuits continue to progress. The Defendants’ witnesses are close to being completed, and expert reports are being prepared. In addition, both parties expect several more trials. The four Federal Court trials were delayed little and should be tried to verdict by early Summer 2017. Several more Philadelphia-based trials are scheduled for the remainder of 2017. It is important to consult an attorney if you have been injured by the drug.
